cyrilzakka/clinical-trials huggingface dataset:
Soft Tissue and Bone Diameter in Children and Adults for Intraosseus Access

Retrospective observational study: Soft tissue and bone diameters are assessed in MRI and CT scans of patients. Data is compared with recommendations of intraosseus needle producers to assess whether the information provided by the producers can be optimised. Study sites are head of humerus bone, distal femur, proximal and distal tibia in accordance with recommended intraosseus access sites.

Primary and secondary outcome parameters will be assessed at one time only, i.e. when the patient has received MRI or CT scan for the diagnostic work up of their primary disease. Data collection for a given patient in this study can be completed within one session, e.g. 5-10 minutes. No additional investigation is required for this retrospective study.

Retrospective observational single centre study: Soft tissue and bone diameters are assessed in MRI and CT scans of patients. Data is compared with recommendations of intraosseus needle producers to assess whether the information provided by the producers can be optimised. Study sites are head of humerus bone, distal femur, proximal and distal tibia in accordance with recommended intraosseus access sites. Data is gathered from patients who undergo either MRI or CT scanning for any disease and where bone at the IO puncture site is accessible for measurements required for this study.

Primary and secondary outcome parameters will be assessed at one time only, i.e. when the patient has received MRI or CT scan for the diagnostic work up of their primary disease. Data collection for a given patient in this study can be completed within one session, e.g. 5-10 minutes. No additional investigation is required for this

Eligibility Criteria:
Inclusion Criteria:

* Patients 0-90 years of age with elective or emergency MRI or CT scan within a 24 months period at the university hospital Innsbruck, Austria. Patients in analgosedation, anaesthesia, and stand-by

Exclusion Criteria:

* Pathologies at recommended intraosseus puncture - and investigation- site, i.e. proximal humerus, distal femur, proximal and distal tibia
Evaluating the Manage My Pain App in Pain Clinics

Chronic Pain is one of the most common reasons adults seek medical care, and has been linked to restrictions in mobility and daily activities, dependence on opioids, anxiety and depression, and poor perceived health or reduced quality of life. Chronic Pain Clinics are an effective solution, however, the resources available and investments have fallen behind the growing needs of patients. Local waitlists have thousands of patients with wait times between 1 to 3 years, with many receiving little to no specialized support while waiting. Tools and technology that can help patients and healthcare providers understand and manage the patients' pain are needed for the effectiveness of the healthcare system.

In response to this problem, the Manage My Pain (MMP) App, which allows patients to log daily reflections of functionality, pain, and medication use; as well as, provide educational resources is a potential support for patients on the waitlist. This log is intended to support the patient understanding and management of their pain, and share their reports with their circle of care.

This study will assess the impact of MMP on waitlist patients' health outcomes compared to a control group of waitlist patients over 60 days.

Chronic Pain is one of the most common reasons adults seek medical care and has been linked to restrictions in mobility and daily activities, dependence on opioids, anxiety, depression, and poor perceived health or reduced quality of life. Currently, local pain clinic waitlists have thousands of patients with wait times between 1 to 3 years, with many receiving little to no specialized support while waiting for an appointment. To address this problem, this study assesses the impact of the MMP App to support the health and medication use of patients on the waitlist. Using this approach patients on the waitlist can use this app to report their pain, functionality, reflections, and medication use, as well as read educational resources about pain management.

This study tests the effectiveness of the MMP App versus a control group (i.e., standard practice) on health outcomes and mediation use over 60 days in a randomized control trial (RCT). The primary outcomes are pain, anxiety, pain self-efficacy, and quality of life. Secondary outcome is medication usage. Researchers will use descriptive and regression analysis to assess the data collected.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* On the Calgary Pain Clinic waitlist

Exclusion Criteria:

* Participants were excluded if they did not meet any of the above criteria
* Patients declining or unable to complete the consent process for the study
* No internet access
* No access to a device or computer to display the app/website
Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)

The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.

Pediatric patients who received caplacizumab will be identified for enrollment in the chart review. The eligibility period starts on August 30, 2018 in the United Kingdom (UK) and France and February 6, 2019 for the United States (US).

Data collection is fully retrospective and will be anchored to the patient's index event date. The index event date is defined as the date the patient initiated caplacizumab treatment. The study period begins at the index date and ends at the earliest date of chart abstraction initiation, 12 weeks after last dose of caplacizumab treatment, date of death, or loss to follow-upwhich ever comes first .

Eligibility Criteria:
Inclusion Criteria:

* Patient's aged ≤18 years at start of caplacizumab treatment initiation
* Patient has a diagnosis of iTTP documented in the medical records
* Patient was treated with caplacizumab within the eligibility period

Exclusion Criteria:

* Patient declined use of data for study (where local regulations require patient notification of planned study)
* Patient's medical chart is missing or not retrievable
Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)

The aim of this study is to assess the developmental patterns of lung function in children affected by growth hormone deficiency after one year of GH therapy.The assessment by specific questionnaires of quality of life and of parental stress index.Parameters will be evaluated at the time of the diagnosis and after 12 months of GH therapy.

Observational longitudinal study in children affected by idiopathic growth hormone deficiency (GHD): lung function parameters assessment; quality of life assessment; stress parenting assessment (Pneumo GHD). The aim of this study is to assess the developmental patterns of lung function in children affected by growth hormone deficiency after one year of GH therapy.The assessment by specific questionnaires of quality of life and of parental stress index.Parameters will be evaluated at the time of the diagnosis and after 12 months of GH therapy.

Eligibility Criteria:
Inclusion Criteria:

* GH deficiency

Exclusion Criteria:

* Respiratory infections 4 weeks before the recruitment
* Children with autoimmune diseases
* Therapy with drugs able to modify the lung function
Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)

Prospective, open labelled, phase II, monocenter trial to combine partial surgery resection and protontherapy to management paediatric craniopharyngioma.

This study is phase II prospective, open labelled, phase ii, monocenter. The main objective is to evaluate the fractionated high precision radiotherapy with a dose of 59,5 Gy (1,7 Gy daily, 5 fractions per week).

Eligibility Criteria:
Inclusion Criteria:

* Histologically documented craniopharyngioma
* Age range between 3 and 16 years
* Landsky performance status \> 60
* Incomplete surgical resection or simple biopsy
* Solid and/or cystic aspect on imaging
* Irradiation performed at the time of presentation or of local progression
* Signed informed consent by parents or by legal representative (with copy to each participating center)

Exclusion Criteria:

* Previous history of radiotherapy (including stereotactic) administered to the head and neck region
* Severe vasculopathy
* Participation to a concurrent study
* Contra-indication to general anesthesia in children below 5 years
* Patient non-compliant to a minimum 30 mn immobilisation
* Patient deprived of freedom or under guardianship
* Patient not expected to be followed in a long run
The Effect of Music Meditation Therapy in Patients With Chronic Pain Receiving Botox

The purpose of this pilot study is to examine the impact of music meditation therapy session on patients with chronic pain who are receiving Botox injections at a pain management center.

This study is a randomized controlled trial (RCT) that employs a two-arm parallel-group design. Ninety-eight participants scheduled to receive a Botox injection will be randomly assigned to receive individual music meditation therapy intervention group or standard care control group before the participant's Botox injection. The study team will use an embedded mixed methods study that uses both quantitative and qualitative data. Qualitative data play a supporting role and are embedded within a larger RCT. The qualitative data will help the investigators better understand the patients' experience of the interventions.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients of both genders ages 18-60 who have been referred for Botox injection for treatment of chronic pain at the Rowan SOM NeuroMusculoskeletal Institute. These patients will have a prior diagnosis made by their physicians necessitating treatment with Botox injections.
* Patients who have previously received a Botox injection or patients receiving Botox injections for the first time can participate.

Exclusion Criteria:

* Patients who cannot speak or understand English for informed consent and patient teaching
* Patients with hearing impairment.
* Pregnant women, children and/or minors, cognitively impaired patients or the elderly (above 60 years of age).
Posterior Capsule Opacification Study

First object is to compare square edge PMMA with round edge PMMA IOL where the materials are same. Next objective is to compare square edge PMMA IOL with Acrysof IOL where the materials are different

Cataract is the vision impairing disease characterized by gradual, progressive thickening of the lens. Posterior Capsular Opacification (PCO) remains the most frequent long term complication. This is initiated by the migration and proliferation of residual lens epithelial cells from the lens equator in the space between the posterior capsule and intraocular lens (IOL)

The combination of IOL material and a sharp edged design is effective in preventing PCO. Aurolab has developed 360 degree square edge IOL with polymethyl methacrylate (PMMA)

100 bilateral senile cataract patients are going to be recruited. First group of 50 patients will receive square edge PMMA in one eye and round edge PMMA in fellow eye. Another group of 50 patients will receive square edge PMMA in one eye and acrysof in fellow eye. PCO will be assessed during each follow up using EPCO software.

Eligibility Criteria:
Inclusion Criteria:

* Age 40 to 65 years
* Bilateral senile cataract
* Pupil should be at least 7mm dilated
* Nuclear sclerosis grade I, II and III
* Patient willing for second eye surgery within 3 months

Exclusion Criteria:

* Debilitated old patients
* Cardiac and serious illness
* Intraoperative complications including PC rent, Zonular dialysis and Rhexis tear
* Inherent zonular weakness
* Glaucoma patients
* Relative afferent papillary defect (RAPD)
* Shallow anterior chamber
* Pseudoexfoliation
* Traumatic cataract
* Uveitis and complicated cataract
* One eyed patients
* Corneal pathology
* Post segment pathology including diabetic retinopathy
* Dense Posterior subcapsular cataract (PSCC) and Posterior polar cataract (PPC)
* High myopic and hyperopic patient
A Single-Arm Trial of Neurovascular Drug-Eluting Balloon Dilatation Catheter Treating Symptomatic Intracranial Atherosclerotic Stenosis

This is a trial designed to test the efficacy and safety of the Neurovascular Drug-Eluting Balloon Dilatation Catheter.

This is a prospective multicentre single-arm trial conducted by 11 centers in mainland China. Approximately 132 subjects with symptomatic intracranial atherosclerotic stenosis receive endovascular treatment using the neurovascular drug-eluting balloon dilatation catheter designed by Zylox.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 80 years, any gender;
* Subject has symptomatic intracranial atherosclerotic stenosis that the degree of the artery stenosis is between 70% and 99% diagnosed by intracranial angiography;
* The target stenotic artery locates in Internal Carotid Artery (intracranial segment), Middle Cerebral Artery (M1, M2), Basilar Artery, Vertebral Artery (intracranial segment);
* Intracranial artery stenosis requiring interventional treatment is a single lesion;
* Subject has at least two atherosclerosis risk factors including history or present hypertension, diabetes, hyperlipidemia, smoking, age\>45;
* modified Rankin Scale(mRS) score≤2 before enrollment;
* Subject or guardian is able to understand the purpose of study, agree to provide follow-up data and has provided written informed consent.

Exclusion Criteria:

* History of acute ischemic stroke within 2 weeks;
* History of intracranial hemorrhage (including intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage and epidural hemorrhage) within 3 months;
* Hypertension uncontrolled by medicine (Systolic pressure≥180 mmHg or diastolic pressure≥110 mmHg continuously);
* Combined with the intracranial tumor, aneurysm or intracranial arteriovenous malformation;
* The length of intracranial artery stenosis \>10mm and extremely angulated \>90°, which indicated by angiography;
* History of stent intervention within the target lesion;
* Allergic to heparin, sirolimus (i.e. rapamycin), contrast agents, aspirin, clopidogrel, anesthetics;
* History of gastrointestinal hemorrhage within 6 months before signing the informed consent form, which is unable to receive antiplatelet therapy;
* Platelet (PLT)\<90\*10\^9/L;
* Creatinine\>250 umol/L;
* International Normalized Ratio (INR)\>1.5;
* Female subject who is pregnant or breast-feeding, or who has a pregnancy plan within 12 months;
* Expected life \<12 months;
* Unable to cooperate with or tolerate the interventional surgery;
* Subject who has participated in other drug or device clinical trials or hasn't reached the primary end point;
* Angiography indicates intracranial artery stenosis caused by arterial dissection, arteritis, and thrombosis;
* Angiography indicates the vascular path is tortuous, the experimental device is difficult to reach the target position or be retracted;
* Other circumstances judged by researchers that are not suitable for enrollment.
Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1

The purpose of this study is to determine the density of DA transporters during prolonged cocaine abuse and during withdrawal from cocaine use. This aim will test the hypothesis that DA transporters are altered by cocaine abuse and reestablished during withdrawal.


Eligibility Criteria:
Please contact site for information.
Pain Informed Movement Program in Patients With Post COVID-19 Condition

Patients who have undergone COVID-19 infection often have long-term sequelae. One of the most prevalent sequelae is pain. The main objective of this research is to investigate the efficacy of Pain Informed Movement program in patients with post COVID-19 condition experiencing persistent pain. Through the implementation of this program, the investigators seek to determine whether such intervention can offer significant improvements in reducing pain intensity and interference, catastrophizing, kinesiophobia, and functionality of affected patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients of both sexes.
* Agreed to participate.
* Post COVID-19 condition patients meeting the WHO definition for this disease.
* Patients with moderate or severe pain were included, the cut-off point on the Visual Analogical Scale (VAS) being pain greater than or equal to 3.5 cm.

Exclusion Criteria:

* Pulmonary, cardiac, neurological, vascular, or orthopaedic pathologies that could limit the execution of the evaluation and intervention.
* Cognitive impairment that prevented them from understanding and answering the questionnaires.
* Patients suffering from a reinfection with SARS-CoV-2.
* Patients with a history of severe or critical COVID-19 disease severity.
* Patients who had pre-existing chronic pain according to the current IASP definition.
* Patients participating in other studies.
Mucormycosis in ICU

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns.

ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU.

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with poor survival and high morbidity ; mortality is estimated between 16% and 64% according to different retrospective studies. No study has ever evaluated prognosis of patients with mucormycosis admitted in intensive care units (ICU).

ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU and to evaluate the prognosis of different subgroups of patients according to :

* their clinical characteristics : demographic characteristics, clinical conditions and factors of immunosuppression
* the characteristics of the fungal infection
* the treatment strategy
* the severity of the initial illness, evaluated by severity scores

Twenty-one French ICU are currently including more than 45 patients.

Eligibility Criteria:
Inclusion Criteria:

* confirmed or suspected mucormycosis, based on international definition from EORTC/MSG
* patient hospitalized in intensive care unit during the 2008-2016 period
* Zygomycosis identification in at least 2 solids organs or identification in hemoculture

Exclusion Criteria:

* Age under 18 years old
* Patient under the law
Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer

Pancreatic cancer is associated with an extremely poor prognosis, reflected by a 5-y survival probability of less than 5% when all stages are combined. At present, only approximately 10%-20% of patients are considered candidates for curative resection. The majority of patients (50%-60%) are present with metastatic disease, and substantial number of patients (approximately 30%-40%) are considered ''locally advanced'' at the time of diagnosis.

Replication-competent Adenovirus-mediated Double Suicide Gene Therapy (Theragene®,Ad5-yCD/mutTKSR39rep-ADP) showed an anti-cancer effect in patients with prostatic cancer in phase I study. From the experience of prostatic cancer, the safety of combination with standard chemotherapy with Theragene treatment is assessed in this study.


Eligibility Criteria:
Inclusion Criteria:

* Patients with pancreatic cancer stage 3
* Patients with histologically confirmed pancreatic adenocarcinoma
* Patients with no evidence of peritoneal or hematogenous metastasis
* Patients with ECOG performance status 0-2
* Patients with renal function (Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 50 mL/min/m²)
* Patients with bone marrow function (WBC \> 4,000/uL or absolute neutrophil count ≥ 1500/uL, PLT ≥ 100,000/uL, and Hemoglobin \> 10 g/dL)
* Patients with liver function (Bilirubin \< 2.0 mg/dL and SGOT and SGPT \< 2.5 times upper limit of normal (ULN))
* Patients with agreement with informed consent
* Male patients with contraception

Exclusion Criteria:

* Female patients with childbearing age or pregnancy or breast feeding
* Patients with a history of chemotherapy within 5 years
* Patients with a history of radiation on more than 25% of bone marrow
* Patients with unknown stage or recurrent pancreatic cancer
* Patients with a history of skin cancer except malignant melanoma or malignancy except stage 0 cervical cancer
* Patients with a history of major surgery except laparoscopic exam, endoscopic ultrasound, stenting, or PEG/PEJ placement
* Patients with active or uncontrolled infection
* Patients with immunosuppression or susceptibility to viral infection
* Patients with HIV infection, chronic hepatitis B, chronic hepatitis C, or liver cirrhosis
* Patients with a history of allergy to clinical trial medications
* Patients who are considered as inappropriate candidate by investigators